Aimovig, erenumab-aooe
Named-patient access overview. Aimovig is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
This page is informational, not medical advice. Always work with a licensed treating physician on prescribing decisions.
About Aimovig
Aimovig is the brand name for erenumab-aooe, a fully human monoclonal antibody developed and co-commercialized by Amgen and Novartis. The US Food and Drug Administration approved Aimovig in May 2018 as the first preventive treatment for migraine designed specifically around the calcitonin gene-related peptide pathway. It is a once-monthly subcutaneous injection delivered through a single-use autoinjector pen.
Aimovig is part of the anti-CGRP class of preventive migraine therapies, which arrived in clinic after decades in which migraine prevention relied on repurposed antihypertensives, antidepressants, and antiepileptics that were never designed for the indication. For patients who have cycled through 2 or more of those older preventives without adequate response, an anti-CGRP option is often the next clinical step.
Mechanism of action
Calcitonin gene-related peptide, or CGRP, is a small protein released during a migraine attack. It dilates blood vessels in the meninges and amplifies pain signaling. Erenumab is engineered to bind the CGRP receptor on the surface of nerve cells, blocking CGRP from docking and triggering the downstream cascade that produces a migraine. Unlike the other approved anti-CGRP antibodies (which bind the CGRP ligand itself), Aimovig is the only one in its class that binds the receptor.
In plain terms: the medicine sits on the doorknob that CGRP would otherwise turn, and refuses to let it open the door.
FDA-approved indications
Aimovig is approved by the FDA for the preventive treatment of migraine in adults. The approved label covers both episodic migraine (fewer than 15 headache days per month) and chronic migraine (15 or more headache days per month, with at least 8 of them being migraine days). It is not approved as an acute treatment, meaning it is not taken to stop an attack already in progress. It is taken on a fixed monthly schedule whether or not a migraine is occurring.
Dosing and administration
The standard starting dose is 70 mg administered subcutaneously once every month. Some patients may benefit from 140 mg once monthly, delivered as either a single 140 mg autoinjector or as two consecutive 70 mg injections. The autoinjector is designed for self-injection at home into the thigh, abdomen, or upper arm after a brief training session. Aimovig must be stored refrigerated between 36 and 46 degrees Fahrenheit and protected from light. It can sit at room temperature for up to 7 days before use if needed, but cannot be returned to the refrigerator afterward.
Side-effect profile
The most commonly reported side effects in clinical trials and post-marketing surveillance are injection-site reactions (redness, mild pain, or itching at the injection point) and constipation. Constipation is worth flagging because in a small subset of patients it can be severe and, in rare cases, has been associated with hospitalization or surgical intervention. Patients with a history of chronic constipation should discuss this with their physician before starting.
Other reported effects include muscle spasms, hypersensitivity reactions, and (rarely) an increase in blood pressure. Aimovig should not be used in patients with known serious hypersensitivity to erenumab or to any of the excipients. As with any biologic, the long-term safety profile continues to be characterized in ongoing post-marketing studies.
Why international patients seek Aimovig cross-border
In several countries served by Reserve Meds, Aimovig is either not yet locally registered, not consistently available, or available only under restrictive payer or formulary criteria that exclude patients who would clearly benefit. Migraine is also significantly under-treated in many of these markets, with most patients still managed on older oral preventives even when those have failed. Named-patient programs and personal-import pathways exist precisely for cases like these: a patient with a clear clinical indication, a treating physician's prescription, and no reasonable access route at home.
Reserve Meds sources Aimovig from DSCSA-compliant US specialty wholesalers, with full serialization and an unbroken cold chain from US warehouse to destination. We do not handle controlled substances. We do not sell direct to consumers. Every Aimovig case is physician-led, documented, and routed through the destination country's lawful import framework.
Start a request for Aimovig
Submit a 60-second intake. Our clinical team will review your case and respond as our first cohort opens with case-specific feasibility, a country pathway, an indicative timeline, and a formal quote. Reserved for you.
Access by country
Reserve Meds publishes a detailed country deep-dive for Aimovig in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.